个人简历
2003年于日本金泽大学获得药学博士学位。2003年-2006年分别在日本名古屋大学和爱知医科大学作为研究员从事研究工作; 2013-2015年在美国加州大学洛杉矶分校(University of California，Los Angeles)作为访问学者从事研究工作。2006年受聘于四川大学生物治疗国家重点实验室，2011年起任研究员和新药早期成药性评价研究室主任。
研究领域
1. 肿瘤发生发展生物标记物鉴定和调控机制研究。2. 小分子靶向抗肿瘤药物研发。3. 新药早期成药性评价。
近期论文
1. Shao X, Lu W, Gao F, Li D, Hu J, Li Y, Zuo Z, Jie H, Zhao Y, Cen X. Uric Acid Induces Cognitive Dysfunction through Hippocampal Inflammation in Rodents andHumans. J Neurosci. 2016 Oct 26;36(43):10990-11005. (IF 5.988) 2. Zhou Y, Li Y, Wang WJ, Xiang P, Luo XM, Yang L, Yang SY, Zhao YL. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides aspotent LSD1 inhibitors. Bioorg Med Chem Lett. 2016 Sep 15;26(18):4552-7. (IF 2.331) 3. Huijuan Wang, Hailong Zhang, Pengchi Deng, Chunqi Liu, Dandan Li, Hui Jie, Hu Zhang, Zongguang Zhou and YingLan Zhao. Tissue metabolic profiling of human gastric cancer assessed by 1H NMR. BMC Cancer. 2016 Jun 29； 16:371. (IF 3.36) 4. Baolai Zhang, Shuhong Dong, Ruiming Zhu, Chunyan Hu, Jing Hou, Yan Li, Qian Zhao, Xue Shao, Qian Bu, Hongyu Li, Yongjie Wu, Xiaobo Cen, Yinglan Zhao. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6(26):22799-811. (IF 6.359) 5. Wenjie Lu, Youzhi Xu, Xiaoni Shao, Fabao Gao, Yan Li, Jing Hu, Zeping Zuo, Xue Shao, Liangxue Zhou, Yinglan Zhao & Xiaobo Cen. Uric Acid Produces an Inflammatory Response through Activation of NF-κB in the Hypothalamus: Implications for the Pathogenesis of Metabolic Disorders. Sci Rep. 2015 Jul 16;5:12144. (IF 5.078) 6. Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, Zhao Y, Yu L. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potentantiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep. 2014 Aug 12;4:6031. (IF 5.078) 7. SKLB-163, new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affectingRhoGDI/JNK-1 signaling pathway. Peng X, Xie G, Wang Z, Lin H, Zhou T, Xiang P, Jiang Y, Yang S, Wei Y, Yu L, Zhao Y. Cell Death Dis. 2014 Mar 27;5:e1143. (IF 5.117) 8. Huijuan Wang, Liang Wang, Hailong Zhang, Pengchi Deng, Jie Chen, Bin Zhou, Jing Hu, Jun Zou, Wenjie Lu, Pu Xiang, Tianming Wu, Xiaoni Shao, Yuan Li, Zongguan Zhou, Ying-Lan Zhao. 1H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer. 2013 Oct 18;12(1):121(IF 5.13) 9. You-zhi Xu, Hong-jun Lin, Na-na Meng, Guobo Li, Wen-jie Lu, Yuan-yuan Han, Xiao-yun dai, Yong Xia, Xiang-rong Song, Sheng-yong Yang, Yu-quan Wei, Luo-ting Yu, Ying-lan Zhao. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Brit J Pharmacol. 2013 Aug;169 (8):1766-80. (IF 5.01) 10.Liang Wang, Jie Chen, Long-Qi Chen, Pengchi Deng, Qian bu, Pu Xiang, Manli Li, Wenjie Lu, Youzhi Xu, Hongjun Lin, Tianming Wu, Huijuan Wang, Jing Hu, Xiaoni Shao, Xiaobo Cen, Ying-Lan Zhao. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol Cancer. 2013 Apr 4; 12: 25. (IF 5.13) 11.Hongjun Lin, Qian Bu, Xiaobo Cen and Ying-Lan Zhao. Current Methods and Research Progress in Nanomaterials Risk Assessment. Curr Drug Meta. 2012 May 1;13 (4):354-63. (IF 5.113)
